A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

July 31, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

RC148 plus Carboplatin and Paclitaxel/pemetrexed

RC148; Carboplatin; Paclitaxel; pemetrexed

DRUG

RC148

RC148 Monotherapy

Trial Locations (24)

Unknown

RECRUITING

Beijing Tiantan Hospital of Capital Medical University, Beijing

RECRUITING

Peking University Cancer Hospital, Beijing

RECRUITING

Shunde Hospital of Southern Medical University, Foshan

RECRUITING

The First People's Hospital of Shunde, Foshan

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

The First affiliated Hospital of Guangzhou Medical University, Guangzhou

RECRUITING

Jiangmen Central Hospital, Jiangmen

RECRUITING

The Second Affiliated Hospital of Guilin Medical College, Gulin

RECRUITING

Affiliated Cancer Hospital of Guangxi Medical University, Nanning

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

RECRUITING

Nanyang Second General Hospital, Hanyang

RECRUITING

The First Affiliated Hospital of Xinxiang Medical College, Xinxiang

RECRUITING

Henan cancer hospital, Zhengzhou

RECRUITING

Union Hospital Tongji Medical College Huazhong University Of Science And Technologe, Wuhan

RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

RECRUITING

Binzhou Medical University Hospital, Binzhou

RECRUITING

Jinan Central Hospital, Jinan

RECRUITING

Linyi Cancer Hospital, Linyi

RECRUITING

Tianjin Medical University Cancer Institute Hospital, Tianjin

RECRUITING

Yunnan Cancer Hospital, Kunming

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

RECRUITING

Taizhou Hospital of Zhejiang Province, Taizhou

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY